Mesenchymal stem cell secretome and nanotechnology: Combining therapeutic strategies

Mesenchymal stem cells (MSC) have pushed the field of cell-based therapies by inducing tissue regeneration, immunosuppression, and angiogenesis mainly through vesicles soluble factors release (paracrine signaling). MSC-extracellular (MSC-EV) adaptable secretome homing to injured sites allowed researchers unlock a new era cell-free based therapy. In parallel, nanoparticles (NP) been explored in contributing transport drug delivery systems, giving drugs desired physical-chemical properties exploit cell behavior. However, NPs can be quickly recognized immune cleared from circulation. this viewpoint, we explore how combining both therapeutic strategies improve efficacy circumvent limitations therapies. MSCEV benefit potent MSC membrane composition, guiding chemotaxis tumor sites, very restricted microenvironment. MSC-EV has low immunogenicity, high stability, long half-life targeting ligands as precise carry, even across biological barriers. Those promote enhanced targeted that combined with NP, exploring production through: 1. direct therapy NP-infused MSC; 2. NP-containing generated 3. coating NP (“MSC NanoGhosts”), allowing cargo definition without losing targeting. Therefore, nanotechnology resources greatly delivery, improving opening venue possibilities.